GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiasma Inc (NAS:CHMA) » Definitions » Owner Earnings per Share (TTM)

Chiasma (Chiasma) Owner Earnings per Share (TTM) : -1.58 (As of Mar. 2021)


View and export this data going back to 2015. Start your Free Trial

What is Chiasma Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Chiasma's Owner Earnings per Share (TTM) ended in Mar. 2021 was $-1.58. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Chiasma's Owner Earnings per Share (TTM) or its related term are showing as below:



CHMA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Chiasma's Earnings per Share (Diluted) for the three months ended in Mar. 2021 was $-0.49. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $-1.61. It's PE Ratio ratio for today is At Loss.

Chiasma's EPS without NRI for the three months ended in Mar. 2021 was $-0.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 was $-1.61. It's PE Ratio without NRI ratio for today is At Loss.


Chiasma Owner Earnings per Share (TTM) Historical Data

The historical data trend for Chiasma's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiasma Owner Earnings per Share (TTM) Chart

Chiasma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - -1.12 -0.93 -1.29

Chiasma Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.05 -1.27 -1.13 -1.29 -1.58

Competitive Comparison of Chiasma's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Chiasma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiasma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiasma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Chiasma's Price-to-Owner-Earnings falls into.



Chiasma Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Chiasma's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -89.94
Depreciation, Depletion and Amortization 0.20
Change In Deferred Tax 0.02
5Y Average of Maintenance Capital Expenditure 0.71
Change In Working Capital -8.51
Shares Outstanding (Diluted Average) 62.83

1. Start with "Net Income" from income statement. Chiasma's Net Income for the trailing twelve months (TTM) ended in Mar. 2021 was $-89.94 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Chiasma's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2021 was $0.20 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Chiasma's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2021 was $0.02 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.71 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Chiasma's 5-Year Average Maintenance Capital Expenditure = $0.71 Mil

5. "Change In Working Capital" is from cashflow statement. Chiasma's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2021 was $-8.51 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Chiasma's Shares Outstanding (Diluted Average) for the months ended in Mar. 2021 was 62.831 Mil.

Chiasma's Onwer Earnings Per Share for Mar. 2021 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -89.941 +0.197+0.023
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.712+-8.505)/62.831
=-1.58

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=3.76/-1.58
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Chiasma Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Chiasma's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiasma (Chiasma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
140 Kendrick Street, Building C East, Needham, MA, USA, 02494
Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.
Executives
Roni Mamluk director CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
David M Stack director THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Bard Geesaman director C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142
Todd Foley director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
John A Scarlett director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Scott Minick director C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139
Anand Varadan officer: EVP, Chief Commerical Officer C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Lee Giguere officer: General Counsel C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
William Ludlam officer: See Remarks C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
Drew Enamait officer: VP, Fin & Admin, PAO C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451
Mark J. Fitzpatrick officer: President 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ansbert Gadicke director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

Chiasma (Chiasma) Headlines